Children with Down Syndrome (DS) have an increased risk of developing leukemia, including both acute myeloid (ML-DS) and acute lymphoblastic leukemia (DS ALL). 1 These leukemias differ in clinical characteristics and biology from leukemias in non-DS children. ML-DS is characterized by a low diagnostic white blood cell (WBC) count, young age, FAB M7 morphology, excellent clinical outcome with survival rates of 490% and a high sensitivity to chemotherapy in vivo and in-vitro.
1,2 ML-DS is often preceded by transient leukemia (TL) in newborns, which in most cases resolves spontaneously. Approximately 20% of TL patients subsequently develop ML-DS. 2 Both the TL and ML-DS blasts are characterized by mutations in the GATA-1 gene, a hematopoietic transcription factor, which result in a truncated protein GATA1s. 3 Because these mutations occur both in TL and ML-DS, additional genetic abnormalities are needed in the progression from TL to ML-DS.
DS ALL patients differ from non-DS ALL children. The distribution of favorable prognostic factors in non-DS ALL, such as high hyperdiploidy and ETV6-RUNX1 gene-rearrangements are less frequently found in DS ALL, as well as unfavorable factors such as Philadelphia-chromosome or MLL-rearrangements. Furthermore, the prognosis of DS ALL patients is at best similar and often inferior to that of non-DS ALL patients. 4 Janus kinases (JAK) belong to a family of intracellular nonreceptor protein tyrosine kinases that transduce cytokinemediated signals through the STAT family of transcription factors. JAK has an important role in regulating the processes of cell proliferation, differentiation and apoptosis in response to growth factors. The JAK2 V617F mutation is well known in myeloproliferative neoplasm and result in the impaired ability of the pseudokinase domain to negatively regulate the kinase domain. 5 Activating mutations in JAK2 and JAK3 in TL and ML-DS have been previously described. 6 Recently, Bercovich et al. 7 and Gaikwad et al. 8 reported activating JAK2 R683 mutations in 18% of DS ALL patients. This mutation was thought to be unique for DS ALL, in a similar fashion as GATA-1 mutations are uniquely found in ML-DS. These activating JAK2 R683 mutations occur at a different site than the V617F mutation, but both these mutations are localized in the pseudokinase domain and both have the same functional consequence, that is, constitutive kinase activity. 7, 8 However, the same JAK2 R683 mutations were also reported in non DS B-cell precursor ALL patients with a high risk for relapse, which implies that this mutation is not specific for DS ALL. 9 As most studies only focus on known mutations in JAK, and hence may underestimate mutational frequency, we performed mutational analysis of the whole kinase and pseudokinase domains of JAK 1-3 by direct sequencing. Moreover, we analyzed the prognostic significance of JAK2 mutations in DS ALL in our cohort. As all cohorts of the prognostic impact of JAK2 mutations in DS ALL are small, we collected all clinical data from these series, 7, 8 and performed a meta-analysis.
We screened six TL, 15 ML-DS (TL and ML-DS samples were unpaired) and 35 DS ALL samples taken at initial diagnosis. TL and ML-DS patients were diagnosed between 1994 and 2007. DS ALL patients were diagnosed between 1992 and 2008 and were treated according to subsequent DCOG treatment protocols ALL 8, 9 and 10. Clinical and cell-biological data, including cytogenetic data, were available for all mutated cases. Samples were provided by the Dutch Childhood Oncology Group, the AML-'Berlin-Frankfurt-Munster' Study Group, and the Nordic Society for Pediatric Hematology and Oncology. All study groups performed central review of the diagnosis, classification and clinical follow-up of the patients. All investigations had been approved by the Institutional Review Board and informed consent was obtained according to local law and regulations.
For mutational analyses, all exons encoding the kinase and pseudokinase domains of JAK1 (exon 12-25), JAK2 (exon 12-25) and JAK3 (exon 12-24) were polymerase chain reaction amplified. All ML-DS and TL samples were screened for GATA-1 mutations in exon 2 and 3. Purified polymerase chain reaction products of JAK 1-3 and GATA-1 were bidirectionally sequenced on an ABI Prism 3100 genetic analyzer (Applied Biosystems Inc., Foster City, CA, USA). The sequence data were assembled and analyzed for mutations using CLC Workbench version 3.5.1 (CLC Bio, Aarhus, Denmark).
All 35 DS ALL patients were classified as B-cell precursor ALL and enrolled in consecutive DCOG treatment protocols (DCOG ALL 8, 9 and 10). The median age of DS ALL patients was 4.5 years (range 2.0-17.1 years), the median WBC was 8.7 Â 10 9 /l (range 1.2-390 Â 10 9 /l) and 51% of the patients were male. The median age of the ML-DS patients was 2.0 years (range 0.7-2.4 years), the median WBC was 8.0 Â 10 9 /l (range 2.6-168 Â 10 9 /l) and 36% were male. The TL patients had a median age of 1.5 days (range 1-6 days) with a median WBC of 172.8 Â 10 9 /l (range 35-410 Â 10 9 /l) and 67% were male. The median follow-up time for survivors with DS ALL was 5.2 years (range 1.1-15.4 years) and for survivors with ML-DS 1.9 years (range 0-16.4 years). The patient characteristics of the TL, ML-DS and DS ALL patients are described in detail in Supplementary Tables S1 and S2 .
Mutations in JAK1 were found in one (7%) ML-DS patient (D625R) and in one (3%) DS ALL patient (V651 M). These were both missense mutations leading to substitution of a single amino acid, which is predicted to result in an altered protein.
No events occurred in either of the patients with a follow-up of 2.4 and 3.1 years, respectively. JAK2 mutations were not identified in any of the TL and ML-DS patients. However, JAK2 R683 activating mutations were found in 6/35 (17%) of the DS ALL patients. In five patients, a substitution of nucleotides A-G was found, which resulted in a substitution of arginine with glycine and one patient had an insertion of nine base pairs (GGCCCCATC), immediately upstream of R683. This specific mutation has not been described before, but two different insertions of multiple base pairs at this position have been reported and were considered to have an effect analogous to R683 mutations because of their location. 7 In DS ALL, cases with JAK2 mutations were significantly younger than the wild type patients, with a median age of 3.2 year versus 4.9 years (P ¼ 0.044). There were no significant differences in other characteristics such as WBC, sex and cytogenetics between the JAK2 mutated and the wild type DS ALL patients. One TL-patient (17%) and one ML-DS patient (7%) harbored the JAK3-A573V mutation. Both patients are in continuous complete remission (CR), with a follow-up of 1.4 and 1.9 years. See Figure 1 for the localization of mutations in JAK 1-3.
The Kaplan-Meier method was used to estimate the 10-year probabilities of overall survival (OS) and event-free survival (EFS); survival estimates were compared using the log-rank test. OS was measured from the date of diagnosis to the date of last follow-up or date of death from any cause. EFS was calculated from the date of diagnosis to the date of last follow-up or to the first event, including relapse, death in CR and failure to achieve CR. Cumulative incidence of relapse (CIR) was constructed by the method of Kalbfleisch and Prentice and compared by the Gray test. None of the six JAK2-mutated DS ALL patients experienced an event, whereas five of the 29 patients with wild type JAK2 relapsed, and one died of treatment-related toxicity. No significant differences in clinical outcome were detected: the 10-year EFS for JAK2-mutated versus JAK2-wild type patients was 100% versus 75±9%, (P ¼ 0.27); the 10-year OS 100% versus 86 ± 7% (P ¼ 0.3). The CIR at 10 years after diagnosis in JAK2-wild type patients was 21 ± 9% versus 0% in the JAK2-mutated group; (p(Gray) ¼ 0.32; Figure 2) . To assess the impact of JAK2 mutations on the survival in a larger cohort of patients, we performed a meta-analysis, pulling our data with those of two published series. Bercovich et al. 7 reported a 5-year EFS of 73% in JAK2-wild type patients (n ¼ 62) versus 78% in JAK2-mutated patients (n ¼ 16), which was also not statistically significant. In addition, Gaikwad et al. 8 described a 5-year EFS in JAK2-wild type patients (n ¼ 43) of 76.3 % versus 87.5% in JAK2-mutated patients (n ¼ 10), again a statistically non-significant difference. Combining their data with ours again did not show a statistically significant difference for the JAK2-wild type versus the JAK2-mutated patients. EFS for 6 years was 71±5% versus 74 ± 10%, P ¼ 0.63 and OS was 76.0 ± 4% versus 89 ± 6%, P ¼ 0.30 (Figures 3a and b) .
In contrast to the non DS B-cell precursor high-risk ALL patients with JAK2 mutations, who were found to have a high relapse rate, 9 none of the JAK2-mutated DS ALL patients in our cohort experienced an event. The observed better outcome for JAK2-mutated patients was, however, not statistically significant. As this meta-analysis includes 32 mutated cases and 139 wild type cases, it provides substantially greater certainty that there is no survival advantage for DS ALL patients with a JAK2 mutation. JAK mutations have a role in activation of the JAK-STAT pathway, resulting in a proliferation advantage for leukemic cells, 7 which led to our initial hypothesis that they would be associated with poor clinical outcome. One possible explanation for the lack of prognostic impact may be that this increased proliferation could contribute to enhanced sensitivity to chemotherapy. However, this is contradictory with the outcome of JAK2 mutants in high-risk ALL, in which patients with a JAK2 mutation have a high risk for relapse. 9 This may be due Letters to the Editor to currently unknown differences in step-wise leukemogenesis, or cooperating genetic events between DS and non-DS JAK2-mutated ALL. Both one TL patient and one ML-DS patient harbored a JAK3-A573V mutation. It has been suggested that JAK3 mutations may be associated with a more aggressive form of ML-DS. 6 However, our two patients with a JAK3 mutation are in continuous CR, with a follow-up of 1.4 and 1.9 years, respectively.
Unfortunately, due to limited availability of our samples, we were not able to show activation of the JAK-STAT pathway at the protein level, and hence we may have missed patients that have JAK-STAT activation due to other mechanisms than mutations in JAK. Hence, further research is needed to identify potential JAK-STAT activation and its causes in DS patients without JAK mutations.
Our study focused on the frequency of mutations in all exons encoding the kinase and pseudokinase domains of JAK 1-3 in DS leukemia patients. We did not detect a higher mutational frequency than previously described, [6] [7] [8] suggesting that there are clear mutational hotspots that can be screened for in clinical studies. However, given the number of patients we have screened, we may still have missed rare mutations that occur in a relatively low frequency in any of these leukemias. Of interest, a meta-analysis confirmed the lack of prognostic significance for JAK2 mutations in DS ALL patients.
